Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Inhibition of the Serotonin Transporter Is Altered by Metabolites of Selective Serotonin and Norepinephrine Reuptake Inhibitors and Represents a Caution to Acute or Chronic Treatment Paradigms.

Krout D, Rodriquez M, Brose SA, Golovko MY, Henry LK, Thompson BJ.

ACS Chem Neurosci. 2017 May 17;8(5):1011-1018. doi: 10.1021/acschemneuro.6b00343. Epub 2016 Dec 28.

2.

Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines.

Mundalil Vasu M, Anitha A, Takahashi T, Thanseem I, Iwata K, Asakawa T, Suzuki K.

PLoS One. 2016 Oct 7;11(10):e0164425. doi: 10.1371/journal.pone.0164425. eCollection 2016.

3.

Receptor and transporter binding and activity profiles of albiflorin extracted from Radix paeoniae Alba.

Jin ZL, Gao N, Xu W, Xu P, Li S, Zheng YY, Xue M.

Sci Rep. 2016 Sep 20;6:33793. doi: 10.1038/srep33793.

4.

Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression.

Schalet BD, Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC.

PLoS One. 2016 Jul 20;11(7):e0159647. doi: 10.1371/journal.pone.0159647. eCollection 2016.

5.

Comparative risk of hip fractures in elderly nursing home patients with depression using paroxetine and other selective serotonin reuptake inhibitors.

Bali V, Chatterjee S, Johnson ML, Chen H, Carnahan RM, Aparasu RR.

J Comp Eff Res. 2016 Aug;5(5):461-73. doi: 10.2217/cer-2016-0009. Epub 2016 Jul 18.

6.

Azidobupramine, an Antidepressant-Derived Bifunctional Neurotransmitter Transporter Ligand Allowing Covalent Labeling and Attachment of Fluorophores.

Kirmeier T, Gopalakrishnan R, Gormanns V, Werner AM, Cuboni S, Rudolf GC, Höfner G, Wanner KT, Sieber SA, Schmidt U, Holsboer F, Rein T, Hausch F.

PLoS One. 2016 Feb 10;11(2):e0148608. doi: 10.1371/journal.pone.0148608. eCollection 2016.

7.

Pharmacological Evaluation of Antidepressant-Like Effect of Genistein and Its Combination with Amitriptyline: An Acute and Chronic Study.

Gupta G, Jia Jia T, Yee Woon L, Kumar Chellappan D, Candasamy M, Dua K.

Adv Pharmacol Sci. 2015;2015:164943. doi: 10.1155/2015/164943. Epub 2015 Nov 22.

8.

Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal Models.

Pytka K, Partyka A, Jastrzębska-Więsek M, Siwek A, Głuch-Lutwin M, Mordyl B, Kazek G, Rapacz A, Olczyk A, Gałuszka A, Błachuta M, Waszkielewicz A, Marona H, Sapa J, Filipek B, Wesołowska A.

PLoS One. 2015 Nov 10;10(11):e0142499. doi: 10.1371/journal.pone.0142499. eCollection 2015.

9.

Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse.

Nackenoff AG, Moussa-Tooks AB, McMeekin AM, Veenstra-VanderWeele J, Blakely RD.

Neuropsychopharmacology. 2016 Jun;41(7):1733-41. doi: 10.1038/npp.2015.335. Epub 2015 Oct 30.

10.

Organic cation transporter 3 contributes to norepinephrine uptake into perivascular adipose tissue.

Ayala-Lopez N, Jackson WF, Burnett R, Wilson JN, Thompson JM, Watts SW.

Am J Physiol Heart Circ Physiol. 2015 Dec 1;309(11):H1904-14. doi: 10.1152/ajpheart.00308.2015. Epub 2015 Oct 2.

11.

Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics.

Kim JR, Woo HI, Chun MR, Lim SW, Kim HD, Na HS, Chung MW, Myung W, Lee SY, Kim DK.

Drug Des Devel Ther. 2015 Sep 16;9:5247-54. doi: 10.2147/DDDT.S84718. eCollection 2015.

12.

A critical evaluation of the activity-regulated cytoskeleton-associated protein (Arc/Arg3.1)'s putative role in regulating dendritic plasticity, cognitive processes, and mood in animal models of depression.

Li Y, Pehrson AL, Waller JA, Dale E, Sanchez C, Gulinello M.

Front Neurosci. 2015 Aug 10;9:279. doi: 10.3389/fnins.2015.00279. eCollection 2015. Review.

13.

Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive Gαi/o Activation in Astroglial Cells.

Hisaoka-Nakashima K, Miyano K, Matsumoto C, Kajitani N, Abe H, Okada-Tsuchioka M, Yokoyama A, Uezono Y, Morioka N, Nakata Y, Takebayashi M.

J Biol Chem. 2015 May 29;290(22):13678-91. doi: 10.1074/jbc.M114.622415. Epub 2015 Apr 13.

14.

Major depressive disorder: mechanism-based prescribing for personalized medicine.

Saltiel PF, Silvershein DI.

Neuropsychiatr Dis Treat. 2015 Mar 31;11:875-88. doi: 10.2147/NDT.S73261. eCollection 2015. Review.

15.

Monoamine reuptake inhibitors in Parkinson's disease.

Huot P, Fox SH, Brotchie JM.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25. Review.

16.
17.

A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Hillhouse TM, Porter JH.

Exp Clin Psychopharmacol. 2015 Feb;23(1):1-21. doi: 10.1037/a0038550. Review.

18.

Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers.

Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR.

J Pharmacol Exp Ther. 2015 Mar;352(3):519-28. doi: 10.1124/jpet.114.220350. Epub 2015 Jan 6.

19.

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Singewald N, Schmuckermair C, Whittle N, Holmes A, Ressler KJ.

Pharmacol Ther. 2015 May;149:150-90. doi: 10.1016/j.pharmthera.2014.12.004. Epub 2014 Dec 27. Review.

20.

Quantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetine.

Margiotta-Casaluci L, Owen SF, Cumming RI, de Polo A, Winter MJ, Panter GH, Rand-Weaver M, Sumpter JP.

PLoS One. 2014 Oct 22;9(10):e110467. doi: 10.1371/journal.pone.0110467. eCollection 2014.

Supplemental Content

Support Center